A Phase 2 Study of SHR-1210 (PD-1 Antibody) in Combination With Apatinib or Chemotherapy (FOLFOX4 or GEMOX) in Subjects With Advanced Primary Liver CancerPLCor Biliary Tract Carcinoma (BTC)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Feb 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Camrelizumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Rivoceranib
Indications Biliary cancer; Gallbladder cancer; Liver cancer
Focus Adverse reactions
Sponsors Jiangsu Hengrui Medicine Co.

26 Apr 2022 Planned End Date changed from 1 Mar 2019 to 1 Apr 2022.
26 Apr 2022 Planned primary completion date changed from 1 Nov 2018 to 1 Apr 2022.
11 Nov 2021 Status changed from recruiting to completed according to results published in the International Journal of Cancer.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com